Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 13/20 | 0.47 |
| ▸ | CA1 | P00915 | 7/20 | 0.46 |
| ▸ | CA2 | P00918 | 7/20 | 0.46 |
| ▸ | CA9 | Q16790 | 7/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23319607 | 0.94 | CA1 (0.49) | LGALS3CA1CA2CA9CA12 | |
| SCHEMBL18839031 | 0.94 | CA1 (0.49) | LGALS3CA1CA2CA9CA12 | |
| SCHEMBL23950968 | 0.93 | CA1 (0.43) | LGALS3CA1CA2CA9CA12 | |
| SCHEMBL23235343 | 0.93 | CA1 (0.43) | LGALS3CA1CA2CA9CA12 | |
| SCHEMBL23950966 | 0.92 | CA1 (0.47) | LGALS3CA1CA2CA9CA12 | |
| SCHEMBL29698543 | 0.92 | CA1 (0.47) | LGALS3CA1CA2CA9CA12 | |
| SCHEMBL22981049 | 0.92 | CA1 (0.47) | LGALS3CA1CA2CA9CA12 | |
| SCHEMBL22979569 | 0.92 | CA1 (0.47) | LGALS3CA1CA2CA9CA12 | |
| SCHEMBL23924592 | 0.91 | CA1 (0.44) | LGALS3CA1CA2CA9CA12 | |
| SCHEMBL20868319 | 0.89 | CA1 (0.47) | LGALS3CA1CA2CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410208-B2 | (2-acetamidyl)thio-beta-D-galactopyranoside derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-09-09 | — | — | US | disclosed |
| US-12404295-B2 | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-09-02 | — | — | US | disclosed |
| EP-4010076-B1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-01-17 | — | — | EP | disclosed |
| EP-4010348-B1 | (2-ACETAMIDYL)THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-20 | — | — | EP | disclosed |
| US-20220315619-A1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-10-06 | — | — | US | disclosed |
| EP-4010348-A1 | (2-ACETAMIDYL)THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2022-06-15 | — | — | EP | disclosed |
| EP-4010076-A1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021028336-A1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021028323-A1 | (2-ACETAMIDYL)THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315619-A1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | LGALS1, LGALS3, LGALS2 | LGALS3 2/4885CA1 3623/4885CA2 2515/4885 |
| US-12410208-B2 | (2-acetamidyl)thio-beta-D-galactopyranoside derivatives | LGALS1, LGALS3, LGALS2 | LGALS3 2/4885CA1 1754/4885CA2 983/4885 |
| US-12404295-B2 | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives | LGALS1, LGALS3, LGALS2 | LGALS3 2/4885CA1 3623/4885CA2 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.